The Venture Codex Logo

The Venture Codex

Helsinn

Via Pian Scairolo 9, Lugano, Ticino, 6912, Switzerland

Overview

Leading cancer care company improving health and quality of life.

Founded

1976

Deals ยท 12mo

1

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A
Series B

Geographic focus

Sweden
Switzerland
United States

Sector focus

Health Care
Pharmaceutical
Therapeutics

Investment portfolio

6rounds
NAMEDATESIZE
AnaCardio
Sep 2026Participated
$71 MSeries B
Amal Therapeutics
Nov 2018Participated
$24 MSeries B
On Target Laboratories
Mar 2018Participated
$11 MSeries B
Amal Therapeutics
Sep 2017Led
$9 MSeries B
Aadi Bioscience
May 2017Participated
$23 MSeries A
MEI Pharma
Aug 2016Led
$5 MOther Equity
AnaCardio
Sep 2026Participated
$71 MSeries B
Amal Therapeutics
Nov 2018Participated
$24 MSeries B
On Target Laboratories
Mar 2018Participated
$11 MSeries B
Amal Therapeutics
Sep 2017Led
$9 MSeries B
Aadi Bioscience
May 2017Participated
$23 MSeries A
MEI Pharma
Aug 2016Led
$5 MOther Equity
6
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Helsinn: 6 funding rounds are recorded in the selected participation categories.All available history.
Helsinn: 6 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01
Series B13
Other Equity10

Monthly Deal Activity

Helsinn: 6 deals are recorded across 123 months.All available history.
Helsinn: 6 deals are recorded across 123 months. All available history
MonthDeals
Aug '161
Sep '160
Oct '160
Nov '160
Dec '160
Jan '170
Feb '170
Mar '170
Apr '170
May '171
Jun '170
Jul '170
Aug '170
Sep '171
Oct '170
Nov '170
Dec '170
Jan '180
Feb '180
Mar '181
Apr '180
May '180
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '181
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '261
Oct '260

Sector Breakdown

Helsinn: Health & Life Sciences is the largest displayed sector by deal count (6 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Helsinn: Health & Life Sciences is the largest displayed sector by deal count (6 deals). All available history
SectorDeals
Health & Life Sciences6
Space & Frontier Tech2

Deal Size Distribution

Helsinn: 6 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Helsinn: 6 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M2
$10M-$25M3
$25M-$50M0
$50M-$100M1
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Helsinn: United States has the largest recorded deal count among the displayed regions (3 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Helsinn: United States has the largest recorded deal count among the displayed regions (3 deals). All available history
RegionDeals
United States3
Europe3
Helsinn: 20 co-investors are shown, with BioMedPartners sharing 2 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Helsinn: 20 co-investors are shown, with BioMedPartners sharing 2 recorded deals. All available history
Co-investorShared deals
BioMedPartners2
Boehringer Ingelheim2
High-Tech Grunderfonds2
Schroder Adveq2
VI Partners2
Celgene1
Decheng Capital1
Elevate Ventures1
Flerie Invest1
H.I.G. BioHealth Partners1
Hermed Capital1
Industrifonden1
Innovestor1
Johnson & Johnson Innovation1
Ljungstrom family office1
LLD Nybohov Invest1
Novo Holdings1
Pureos Bioventures1
Sound Bioventures1
Star Summit Ventures1

Investment Strategy

Helsinn: Led accounts for 33% and participating for 67% of round participation.All available history.
Helsinn: Led accounts for 33% and participating for 67% of round participation. All available history
CategoryDeals (count)Share (%)
Led233%
Participating467%
Helsinn: Single-lead accounts for 50% and co-led for 50% of lead dynamics.All available history.
Helsinn: Single-lead accounts for 50% and co-led for 50% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead150%
Co-led150%

Team

Gabriele Braglia

Founder and Manager

Georg Buchner

Group Chief Business Officer

Konrad Wilson

Group CFO

Matteo Missaglia

Group General Counsel and Group Chief Legal Officer

Melanie Rolli

Group Chief Operating Officer

Rachid Benhamza

Director, Alliance Management

Roberta Cannella

Group Chief Manufacturing Officer and Corporate Pharmaceutical Technology Director

Sergio Cantoreggi

Group Chief Scientific Officer and Global Head of Research and Development